Bill Text: IL HB5526 | 2013-2014 | 98th General Assembly | Introduced

NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: Amends the Illinois Controlled Substances Act. Makes kratom (including any parts of the plant Mitragyna speciosa, whether growing or not, and any compound, manufacture, salt, derivative, mixture, or preparation of that plant, including but not limited to mitragynine and 7-hydroxymitragynine) a Schedule I controlled substance.

Spectrum: Partisan Bill (Republican 4-0)

Status: (Passed) 2014-08-18 - Public Act . . . . . . . . . 98-0981 [HB5526 Detail]

Download: Illinois-2013-HB5526-Introduced.html


98TH GENERAL ASSEMBLY
State of Illinois
2013 and 2014
HB5526

Introduced , by Rep. Dennis M. Reboletti

SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204

Amends the Illinois Controlled Substances Act. Makes kratom (including any parts of the plant Mitragyna speciosa, whether growing or not, and any compound, manufacture, salt, derivative, mixture, or preparation of that plant, including but not limited to mitragynine and 7-hydroxymitragynine) a Schedule I controlled substance.
LRB098 15322 RLC 50351 b
CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY

A BILL FOR

HB5526LRB098 15322 RLC 50351 b
1 AN ACT concerning criminal law.
2 Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 204 as follows:
6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
7 Sec. 204. (a) The controlled substances listed in this
8Section are included in Schedule I.
9 (b) Unless specifically excepted or unless listed in
10another schedule, any of the following opiates, including their
11isomers, esters, ethers, salts, and salts of isomers, esters,
12and ethers, whenever the existence of such isomers, esters,
13ethers and salts is possible within the specific chemical
14designation:
15 (1) Acetylmethadol;
16 (1.1) Acetyl-alpha-methylfentanyl
17 (N-[1-(1-methyl-2-phenethyl)-
18 4-piperidinyl]-N-phenylacetamide);
19 (2) Allylprodine;
20 (3) Alphacetylmethadol, except
21 levo-alphacetylmethadol (also known as levo-alpha-
22 acetylmethadol, levomethadyl acetate, or LAAM);
23 (4) Alphameprodine;

HB5526- 2 -LRB098 15322 RLC 50351 b
1 (5) Alphamethadol;
2 (6) Alpha-methylfentanyl
3 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
5 propanilido) piperidine;
6 (6.1) Alpha-methylthiofentanyl
7 (N-[1-methyl-2-(2-thienyl)ethyl-
8 4-piperidinyl]-N-phenylpropanamide);
9 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10 (7.1) PEPAP
11 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
12 (8) Benzethidine;
13 (9) Betacetylmethadol;
14 (9.1) Beta-hydroxyfentanyl
15 (N-[1-(2-hydroxy-2-phenethyl)-
16 4-piperidinyl]-N-phenylpropanamide);
17 (10) Betameprodine;
18 (11) Betamethadol;
19 (12) Betaprodine;
20 (13) Clonitazene;
21 (14) Dextromoramide;
22 (15) Diampromide;
23 (16) Diethylthiambutene;
24 (17) Difenoxin;
25 (18) Dimenoxadol;
26 (19) Dimepheptanol;

HB5526- 3 -LRB098 15322 RLC 50351 b
1 (20) Dimethylthiambutene;
2 (21) Dioxaphetylbutyrate;
3 (22) Dipipanone;
4 (23) Ethylmethylthiambutene;
5 (24) Etonitazene;
6 (25) Etoxeridine;
7 (26) Furethidine;
8 (27) Hydroxpethidine;
9 (28) Ketobemidone;
10 (29) Levomoramide;
11 (30) Levophenacylmorphan;
12 (31) 3-Methylfentanyl
13 (N-[3-methyl-1-(2-phenylethyl)-
14 4-piperidyl]-N-phenylpropanamide);
15 (31.1) 3-Methylthiofentanyl
16 (N-[(3-methyl-1-(2-thienyl)ethyl-
17 4-piperidinyl]-N-phenylpropanamide);
18 (32) Morpheridine;
19 (33) Noracymethadol;
20 (34) Norlevorphanol;
21 (35) Normethadone;
22 (36) Norpipanone;
23 (36.1) Para-fluorofentanyl
24 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
25 4-piperidinyl]propanamide);
26 (37) Phenadoxone;

HB5526- 4 -LRB098 15322 RLC 50351 b
1 (38) Phenampromide;
2 (39) Phenomorphan;
3 (40) Phenoperidine;
4 (41) Piritramide;
5 (42) Proheptazine;
6 (43) Properidine;
7 (44) Propiram;
8 (45) Racemoramide;
9 (45.1) Thiofentanyl
10 (N-phenyl-N-[1-(2-thienyl)ethyl-
11 4-piperidinyl]-propanamide);
12 (46) Tilidine;
13 (47) Trimeperidine;
14 (48) Beta-hydroxy-3-methylfentanyl (other name:
15 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
16 N-phenylpropanamide).
17 (c) Unless specifically excepted or unless listed in
18another schedule, any of the following opium derivatives, its
19salts, isomers and salts of isomers, whenever the existence of
20such salts, isomers and salts of isomers is possible within the
21specific chemical designation:
22 (1) Acetorphine;
23 (2) Acetyldihydrocodeine;
24 (3) Benzylmorphine;
25 (4) Codeine methylbromide;
26 (5) Codeine-N-Oxide;

HB5526- 5 -LRB098 15322 RLC 50351 b
1 (6) Cyprenorphine;
2 (7) Desomorphine;
3 (8) Diacetyldihydromorphine (Dihydroheroin);
4 (9) Dihydromorphine;
5 (10) Drotebanol;
6 (11) Etorphine (except hydrochloride salt);
7 (12) Heroin;
8 (13) Hydromorphinol;
9 (14) Methyldesorphine;
10 (15) Methyldihydromorphine;
11 (16) Morphine methylbromide;
12 (17) Morphine methylsulfonate;
13 (18) Morphine-N-Oxide;
14 (19) Myrophine;
15 (20) Nicocodeine;
16 (21) Nicomorphine;
17 (22) Normorphine;
18 (23) Pholcodine;
19 (24) Thebacon.
20 (d) Unless specifically excepted or unless listed in
21another schedule, any material, compound, mixture, or
22preparation which contains any quantity of the following
23hallucinogenic substances, or which contains any of its salts,
24isomers and salts of isomers, whenever the existence of such
25salts, isomers, and salts of isomers is possible within the
26specific chemical designation (for the purposes of this

HB5526- 6 -LRB098 15322 RLC 50351 b
1paragraph only, the term "isomer" includes the optical,
2position and geometric isomers):
3 (1) 3,4-methylenedioxyamphetamine
4 (alpha-methyl,3,4-methylenedioxyphenethylamine,
5 methylenedioxyamphetamine, MDA);
6 (1.1) Alpha-ethyltryptamine
7 (some trade or other names: etryptamine;
8 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
9 3-(2-aminobutyl)indole; a-ET; and AET);
10 (2) 3,4-methylenedioxymethamphetamine (MDMA);
11 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
12 (also known as: N-ethyl-alpha-methyl-
13 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
14 and MDEA);
15 (2.2) N-Benzylpiperazine (BZP);
16 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
17 (4) 3,4,5-trimethoxyamphetamine (TMA);
18 (5) (Blank);
19 (6) Diethyltryptamine (DET);
20 (7) Dimethyltryptamine (DMT);
21 (7.1) 5-Methoxy-diallyltryptamine;
22 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
23 (9) Ibogaine (some trade and other names:
24 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
25 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
26 indole; Tabernanthe iboga);

HB5526- 7 -LRB098 15322 RLC 50351 b
1 (10) Lysergic acid diethylamide;
2 (10.1) Salvinorin A;
3 (10.5) Salvia divinorum (meaning all parts of the plant
4 presently classified botanically as Salvia divinorum,
5 whether growing or not, the seeds thereof, any extract from
6 any part of that plant, and every compound, manufacture,
7 salts, isomers, and salts of isomers whenever the existence
8 of such salts, isomers, and salts of isomers is possible
9 within the specific chemical designation, derivative,
10 mixture, or preparation of that plant, its seeds or
11 extracts);
12 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
13 (12) Peyote (meaning all parts of the plant presently
14 classified botanically as Lophophora williamsii Lemaire,
15 whether growing or not, the seeds thereof, any extract from
16 any part of that plant, and every compound, manufacture,
17 salts, derivative, mixture, or preparation of that plant,
18 its seeds or extracts);
19 (13) N-ethyl-3-piperidyl benzilate (JB 318);
20 (14) N-methyl-3-piperidyl benzilate;
21 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
22 (also known as N-hydroxy-alpha-methyl-
23 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
24 (15) Parahexyl; some trade or other names:
25 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
26 dibenzo (b,d) pyran; Synhexyl;

HB5526- 8 -LRB098 15322 RLC 50351 b
1 (16) Psilocybin;
2 (17) Psilocyn;
3 (18) Alpha-methyltryptamine (AMT);
4 (19) 2,5-dimethoxyamphetamine
5 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
6 (20) 4-bromo-2,5-dimethoxyamphetamine
7 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
8 4-bromo-2,5-DMA);
9 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
10 Some trade or other names: 2-(4-bromo-
11 2,5-dimethoxyphenyl)-1-aminoethane;
12 alpha-desmethyl DOB, 2CB, Nexus;
13 (21) 4-methoxyamphetamine
14 (4-methoxy-alpha-methylphenethylamine;
15 paramethoxyamphetamine; PMA);
16 (22) (Blank);
17 (23) Ethylamine analog of phencyclidine.
18 Some trade or other names:
19 N-ethyl-1-phenylcyclohexylamine,
20 (1-phenylcyclohexyl) ethylamine,
21 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
22 (24) Pyrrolidine analog of phencyclidine. Some trade
23 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
24 PHP;
25 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
26 (26) 2,5-dimethoxy-4-ethylamphetamine

HB5526- 9 -LRB098 15322 RLC 50351 b
1 (another name: DOET);
2 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
3 (another name: TCPy);
4 (28) (Blank);
5 (29) Thiophene analog of phencyclidine (some trade
6 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
7 2-thienyl analog of phencyclidine; TPCP; TCP);
8 (30) Bufotenine (some trade or other names:
9 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
10 3-(2-dimethylaminoethyl)-5-indolol;
11 5-hydroxy-N,N-dimethyltryptamine;
12 N,N-dimethylserotonin; mappine);
13 (31) 1-Pentyl-3-(1-naphthoyl)indole
14 Some trade or other names: JWH-018;
15 (32) 1-Butyl-3-(1-naphthoyl)indole
16 Some trade or other names: JWH-073;
17 (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]-
18 (2-iodophenyl)methanone
19 Some trade or other names: AM-694;
20 (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
21 (2-methyloctan-2-yl)phenol
22 Some trade or other names: CP 47,497
23 and its C6, C8 and C9 homologs;
24 (34.5) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
25 (2-methyloctan-2-yl)phenol), where side chain n=5;
26 and homologues where side chain n=4, 6, or 7; Some

HB5526- 10 -LRB098 15322 RLC 50351 b
1 trade or other names: CP 47,497;
2 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
3 (2-methyloctan-2-yl)-6a,7,
4 10,10a-tetrahydrobenzo[c]chromen-1-ol
5 Some trade or other names: HU-210;
6 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
7 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
8 tetrahydrobenzo[c]chromen-1-ol, its isomers,
9 salts, and salts of isomers; Some trade or other
10 names: HU-210, Dexanabinol;
11 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
12 6,6-dimethyl-3-(2-methyloctan-2-yl)-
13 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
14 Some trade or other names: HU-211;
15 (37) (2-methyl-1-propyl-1H-indol-
16 3-yl)-1-naphthalenyl-methanone
17 Some trade or other names: JWH-015;
18 (38) 4-methoxynaphthalen-1-yl-
19 (1-pentylindol-3-yl)methanone
20 Some trade or other names: JWH-081;
21 (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
22 Some trade or other names: JWH-122;
23 (40) 2-(2-methylphenyl)-1-(1-pentyl-
24 1H-indol-3-yl)-ethanone
25 Some trade or other names: JWH-251;
26 (41) 1-(2-cyclohexylethyl)-3-

HB5526- 11 -LRB098 15322 RLC 50351 b
1 (2-methoxyphenylacetyl)indole
2 Some trade or other names: RCS-8, BTW-8 and SR-18;
3 (42) Any compound structurally derived from
4 3-(1-naphthoyl)indole or 1H-indol-3-yl-
5 (1-naphthyl)methane by substitution at the
6 nitrogen atom of the indole ring by alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl or
8 2-(4-morpholinyl)ethyl whether or not further
9 substituted in the indole ring to any extent, whether
10 or not substituted in the naphthyl ring to any extent;
11 (43) Any compound structurally derived from
12 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
13 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl or
15 2-(4-morpholinyl)ethyl, whether or not further
16 substituted in the pyrrole ring to any extent, whether
17 or not substituted in the naphthyl ring to any extent;
18 (44) Any compound structurally derived from
19 1-(1-naphthylmethyl)indene by substitution
20 at the 3-position of the indene ring by alkyl, haloalkyl,
21 alkenyl, cycloalkylmethyl, cycloalkylethyl or
22 2-(4-morpholinyl)ethyl whether or not further
23 substituted in the indene ring to any extent, whether
24 or not substituted in the naphthyl ring to any extent;
25 (45) Any compound structurally derived from
26 3-phenylacetylindole by substitution at the

HB5526- 12 -LRB098 15322 RLC 50351 b
1 nitrogen atom of the indole ring with alkyl, haloalkyl,
2 alkenyl, cycloalkylmethyl, cycloalkylethyl or
3 2-(4-morpholinyl)ethyl, whether or not further
4 substituted in the indole ring to any extent, whether
5 or not substituted in the phenyl ring to any extent;
6 (46) Any compound structurally derived from
7 2-(3-hydroxycyclohexyl)phenol by substitution
8 at the 5-position of the phenolic ring by alkyl,
9 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl
10 or 2-(4-morpholinyl)ethyl, whether or not substituted
11 in the cyclohexyl ring to any extent;
12 (47) 3,4-Methylenedioxymethcathinone
13 Some trade or other names: Methylone;
14 (48) 3,4-Methyenedioxypyrovalerone
15 Some trade or other names: MDPV;
16 (49) 4-Methylmethcathinone
17 Some trade or other names: Mephedrone;
18 (50) 4-methoxymethcathinone;
19 (51) 4-Fluoromethcathinone;
20 (52) 3-Fluoromethcathinone;
21 (53) 2,5-Dimethoxy-4-(n)-propylthio-
22 phenethylamine;
23 (54) 5-Methoxy-N,N-diisopropyltryptamine;
24 (55) Pentedrone.
25 (e) Unless specifically excepted or unless listed in
26another schedule, any material, compound, mixture, or

HB5526- 13 -LRB098 15322 RLC 50351 b
1preparation which contains any quantity of the following
2substances having a depressant effect on the central nervous
3system, including its salts, isomers, and salts of isomers
4whenever the existence of such salts, isomers, and salts of
5isomers is possible within the specific chemical designation:
6 (1) mecloqualone;
7 (2) methaqualone; and
8 (3) gamma hydroxybutyric acid.
9 (f) Unless specifically excepted or unless listed in
10another schedule, any material, compound, mixture, or
11preparation which contains any quantity of the following
12substances having a stimulant effect on the central nervous
13system, including its salts, isomers, and salts of isomers:
14 (1) Fenethylline;
15 (2) N-ethylamphetamine;
16 (3) Aminorex (some other names:
17 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
18 4-5-dihydro-5-phenyl-2-oxazolamine) and its
19 salts, optical isomers, and salts of optical isomers;
20 (4) Methcathinone (some other names:
21 2-methylamino-1-phenylpropan-1-one;
22 Ephedrone; 2-(methylamino)-propiophenone;
23 alpha-(methylamino)propiophenone; N-methylcathinone;
24 methycathinone; Monomethylpropion; UR 1431) and its
25 salts, optical isomers, and salts of optical isomers;
26 (5) Cathinone (some trade or other names:

HB5526- 14 -LRB098 15322 RLC 50351 b
1 2-aminopropiophenone; alpha-aminopropiophenone;
2 2-amino-1-phenyl-propanone; norephedrone);
3 (6) N,N-dimethylamphetamine (also known as:
4 N,N-alpha-trimethyl-benzeneethanamine;
5 N,N-alpha-trimethylphenethylamine);
6 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
7 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
8 (8) 3,4-Methylenedioxypyrovalerone (MDPV).
9 (g) Temporary listing of substances subject to emergency
10scheduling. Any material, compound, mixture, or preparation
11that contains any quantity of the following substances:
12 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
13 (benzylfentanyl), its optical isomers, isomers, salts,
14 and salts of isomers;
15 (2) N-[1(2-thienyl)
16 methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
17 its optical isomers, salts, and salts of isomers.
18 (h) Unless specifically excepted or unless listed in
19another schedule, any material, compound, mixture, or
20preparation which contains any quantity of kratom (including
21any parts of the plant Mitragyna speciosa, whether growing or
22not, and any compound, manufacture, salt, derivative, mixture,
23or preparation of that plant, including but not limited to
24mitragynine and 7-hydroxymitragynine).
25(Source: P.A. 96-347, eff. 1-1-10; 96-1285, eff. 1-1-11;
2697-192, eff. 7-22-11; 97-193, eff. 1-1-12; 97-194, eff.

HB5526- 15 -LRB098 15322 RLC 50351 b
17-22-11; 97-334, eff. 1-1-12; 97-813, eff. 7-13-12; 97-872,
2eff. 7-31-12.)
feedback